Nachrichten zur IPSEN S.A. PORT. EO 1 Aktie

Annual General Meeting of Ipsen S.A. held on 28 May 2024

PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today…

Radiotheranostics Market Current Trends and Future Scope Analysis Report

Companies covered in this report are TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc.,…

IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2023

Aggregated presentation by day and by market...…

Exelixis, Ipsen Say Prostate Cancer Phase 3 Trial Met One of Two Main Goals

Exelixis, Ipsen Say Prostate Cancer Phase 3 Trial Met One of Two Main Goals...…

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared…

Ipsen wins FDA approval of rare bone disease drug palovarotene

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2023

Aggregated presentation by day and by market...…

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2023

Aggregated presentation by day and by market...…

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital...…

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2023

Aggregated presentation by day and by market...…

Ipsen S.A. publishes its 2023 Half-Year Financial Report

Ipsen S.A. publishes its 2023 Half-Year Financial Report...…

Ipsen S.A. GAAP EPS of €2.35, revenue of €1.54B

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ipsen Shares Rise After It Upgrades 2023 Outlook

Ipsen Shares Rise After It Upgrades 2023 Outlook...…

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

Paris, France: 27 July 2023Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, presents today its financial results for…

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2023

Aggregated presentation by day and by market...…

Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023

PARIS, FRANCE, 24 July 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) announced today that the Board of Directors of Ipsen…

Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome

PARIS, FRANCE, 21 July 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the European Medicines Agencys (EMA) Committee…

Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome

PARIS, FRANCE, 21 July 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the European Medicines Agencys (EMA) Committee…

Ipsen bone disorder therapy rejected in EU

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ipsen says European Commission rejects marketing authorization for bone disorder drug

...(Reuters) - French drugmaker Ipsen said on Wednesday the European......…

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

PARIS, FRANCE, 19 July 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has followed guidance…

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023

Aggregated presentation by day and by market...…

IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2023

Aggregated presentation by day and by market...…

Ipsen – Half year statement – 2023 06 30

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...…

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

...…

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2023

Aggregated presentation by day and by market...…

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

The U.S.-listed stock of Genfit S.A. GNFTFR:GNFT soared 27% premarket Friday, after the French biotech and partner Ipsen IPSEYFR:IPN announced…

Ipsen wins FDA AdCom nod for bone disease therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ipsen Shares Rise After FDA Panel Backs Drug for Rare Bone Disease

Ipsen Shares Rise After FDA Panel Backs Drug for Rare Bone Disease...…

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administrations…

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2023

Aggregated presentation by day and by market...…

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2023

Aggregated presentation by day and by market...…

Ipsen acaba de aprovar Bylvay® no Brasil, após a conclusão da aquisição da Albireo

A aprovação dessa droga, fruto da aquisição da Albireo, representa uma oportunidade de crescimento para a Ipsen e reforça o…

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

PARIS, FRANCE, 14 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration…

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

PARIS, FRANCE, 14 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration…

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2023

Aggregated presentation by day and by market...…

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023

PARIS, FRANCE, 12 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the company will present data from…

dpa-AFX ProFeed